Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 1/20 | 0.37 |
| ▸ | GRIA1 | P42261 | 3/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | RELA | Q04206 | 4/20 | 0.30 |
| ▸ | ANPEP | P15144 | 2/20 | 0.30 |
| ▸ | RNPEP | Q9H4A4 | 2/20 | 0.30 |
| ▸ | DNPEP | Q9ULA0 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.30 |
| ▸ | PDE4A | P27815 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1832543 | 0.90 | GRIA1 (0.36) | APPGRIA1CA2EPHX2ALDH1A1 | |
| SCHEMBL1831247 | 0.90 | GRIA1 (0.36) | APPGRIA1CA2EPHX2ALDH1A1 | |
| SCHEMBL14100075 | 0.88 | POLB (0.33) | APPGRIA1POLBALDH1A1ANPEP | |
| SCHEMBL5261111 | 0.83 | APP (0.33) | APPGRIA1CA2EPHX2ALDH1A1 | |
| SCHEMBL918312 | 0.82 | APP (0.50) | APPCA2EPHX2ALDH1A1TSHR | |
| SCHEMBL918218 | 0.82 | APP (0.35) | APPGRIA1EPHX2ALDH1A1TSHR | |
| SCHEMBL30693683 | 0.82 | GRIA1 (0.36) | GRIA1CA2EPHX2ALDH1A1TP53 | |
| SCHEMBL5262548 | 0.82 | APP (0.32) | APPALDH1A1TP53 | |
| SCHEMBL10278042 | 0.82 | APP (0.36) | APPCA2TP53RELACYP2C19 | |
| SCHEMBL917453 | 0.82 | CA2 (0.46) | APPGRIA1CA2EPHX2ANPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230143708-A1 | ANTIMICROBIAL ORGANOSILANES | TOPIKOS PHARMACEUTICALS, INC. (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230135723-A1 | ANTI-CD98 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | ABBVIE INC (US) | 2023-05-04 | — | — | US | disclosed |
| US-20210171637-A1 | ANTI-B7-H3 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | ABBVIE INC. | 2021-06-10 | — | — | US | disclosed |
| WO-2021077119-A1 | ANTIMICROBIAL ORGANOSILANES | TOPIKOS PHARMACEUTICALS, INC. (US) | 2021-04-22 | — | — | WO | disclosed |
| US-20200246460-A1 | BCL-XL Inhibitory Compounds Having Low Cell Permeability and Antibody Drug Conjugates Including the Same | ABBVIE INC (US) | 2020-08-06 | — | — | US | disclosed |
| US-20190343961-A1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | ABBVIE INC. | 2019-11-14 | — | — | US | disclosed |
| US-20190142941-A1 | BCL-XL Inhibitory Compounds Having Low Cell Permeability and Antibody Drug Conjugates Including the Same | ABBVIE INC (US) | 2019-05-16 | — | — | US | disclosed |
| CN-101597196-B | Improved drug candidate and preparation method thereof | JIYAKETA CO., LTD. (CH) | 2016-05-04 | — | — | CN | disclosed |
| US-20140329746-A1 | METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2014-11-06 | — | — | US | disclosed |
| US-20140329746-A1 | METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2014-11-06 | — | — | US | disclosed |
| US-20070010573-A1 | Methods and compositions for treating amyloid-related diseases | BELLUS HEALTH (INTERNATIONAL) LIMITED (CH) | 2007-01-11 | — | — | US | disclosed |
| US-20070010573-A1 | Methods and compositions for treating amyloid-related diseases | BELLUS HEALTH (INTERNATIONAL) LIMITED (CH) | 2007-01-11 | — | — | US | disclosed |
| CN-1839117-A | Improved drug candidates and methods for their preparation | NEUROCHEM INTERNAT LTD (CH) | 2006-09-27 | — | — | CN | disclosed |
| US-20060135403-A1 | Therapeutic formulations for the treatment of beta-amyloid related diseases | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2006-06-22 | — | — | US | disclosed |
| EP-1646659-A2 | IMPROVED PHARMACEUTICAL DRUG CANDIDATES AND METHODS FOR PREPARATION THEREOF | Neurochem (International) Limited (CH) | 2006-04-19 | — | — | EP | disclosed |
| EP-1644325-A2 | METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | Neurochem (International) Limited (CH) | 2006-04-12 | — | — | EP | disclosed |
| US-20050143462-A1 | Pharmaceutical drug candidates and methods for preparation thereof | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2005-06-30 | — | — | US | disclosed |
| US-20050096385-A1 | Methods and compositions for treating amyloid-related diseases | BHI LIMITED PARTNERSHIP (CA) | 2005-05-05 | — | — | US | disclosed |
| WO-2004113391-A2 | IMPROVED PHARMACEUTICAL DRUG CANDIDATES AND METHODS FOR PREPARATION THEREOF | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2004-12-29 | — | — | WO | disclosed |
| WO-2004113275-A2 | METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2004-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210171637-A1 | ANTI-B7-H3 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | HRH3, H1-3, CD274 | APP 3623/4885GRIA1 1707/4885CA2 4090/4885 |
| US-20230135723-A1 | ANTI-CD98 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | CD99, SLC3A2, CD63 | APP 4229/4885GRIA1 1776/4885CA2 1226/4885 |
| US-20200246460-A1 | BCL-XL Inhibitory Compounds Having Low Cell Permeability and Antibody Drug Conjugates Including the Same | BCL2, BAX, BCL9 | APP 3533/4885GRIA1 4536/4885CA2 2615/4885 |
| US-20060135403-A1 | Therapeutic formulations for the treatment of beta-amyloid related diseases | APP, IAPP, BACE1 | APP 1/4885GRIA1 2942/4885CA2 3208/4885 |
| US-20050143462-A1 | Pharmaceutical drug candidates and methods for preparation thereof | MPST, TTR, STS | APP 86/4885GRIA1 3506/4885CA2 1636/4885 |
| US-20140329746-A1 | METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | APP, PSEN1, PSEN2 | APP 1/4885GRIA1 3229/4885CA2 1085/4885 |
| US-20230143708-A1 | ANTIMICROBIAL ORGANOSILANES | ARG1, ACMSD, AAAS | APP 4125/4885GRIA1 3789/4885CA2 2548/4885 |
| US-20190343961-A1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | EGFR, ERBB2, ERBB3 | APP 3714/4885GRIA1 1478/4885CA2 2461/4885 |
| US-20190142941-A1 | BCL-XL Inhibitory Compounds Having Low Cell Permeability and Antibody Drug Conjugates Including the Same | BCL2, BAX, BCL9 | APP 3533/4885GRIA1 4536/4885CA2 2615/4885 |
| US-20050096385-A1 | Methods and compositions for treating amyloid-related diseases | APP, PSEN1, PSEN2 | APP 1/4885GRIA1 3229/4885CA2 1085/4885 |
| US-20070010573-A1 | Methods and compositions for treating amyloid-related diseases | APP, PSEN1, PSEN2 | APP 1/4885GRIA1 3229/4885CA2 1085/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.